- ISIN
- US75629V1044
- CUSIP
- 75629V104
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Apr 16, 2021
Highlights
- Market Cap
- $1.57B
- Enterprise Value
- $1.01B
- EPS (TTM)
- -$1.12
- Total Revenue (TTM)
- $66.29M
- Gross Profit (TTM)
- -$22.83M
- EBITDA (TTM)
- -$505.90M
- Year Range
- $2.77 - $7.18
- Target Price
- $11.00
- ROA (TTM)
- -41.79%
- ROE (TTM)
- -54.62%
- Avg. Volume (1M)
- 22M
- Avg. Volume Value (1M)
- $74.51M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
RXRX Performance Chart
Recursion Pharmaceuticals, Inc. (RXRX) is down 26.7% since the beginning of the year. At $3 per share, RXRX is trading 58.2% below its 52-week high of $7. Investors who bought $1,000 worth of RXRX shares 5 years ago would now be looking at an investment worth $99.
Loading charts...
Compare this symbol against anything
Returns By Period
Recursion Pharmaceuticals, Inc. (RXRX) has returned -26.65% so far this year and -47.18% over the past 12 months.
Recursion Pharmaceuticals, Inc.
- 1D
- -1.32%
- 1M
- -21.05%
- 6M
- -28.40%
- YTD
- -26.65%
- 1Y
- -47.18%
- 3Y*
- -39.89%
- 5Y*
- -37.05%
- 10Y*
- —
- ALL TIME*
- -35.29%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
RXRX Monthly Returns History
Based on dividend-adjusted daily data since Apr 16, 2021, RXRX's average daily return is -0.01%, while the average monthly return is -1.01%.
Historically, 41% of months were positive and 59% were negative. The best month was Jul 2023 with a return of +89.0%, while the worst month was Aug 2023 at -38.4%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 11 months.
On a daily basis, RXRX closed higher 47% of trading days. The best single day was Jul 12, 2023 with a return of +78.2%, while the worst single day was Mar 4, 2022 at -21.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 2.44% | -12.41% | -16.35% | 12.70% | 3.76% | 2.23% | -18.26% | -26.65% | |||||
| 2025 | 7.10% | 3.73% | -29.56% | 5.67% | -25.22% | 21.05% | 17.59% | -21.01% | 3.83% | 13.11% | -16.12% | -11.66% | -39.50% |
| 2024 | -4.56% | 43.04% | -25.93% | -21.56% | 5.88% | -9.42% | 9.33% | -11.22% | -9.48% | -4.10% | 11.87% | -4.38% | -31.44% |
| 2023 | 8.04% | -2.16% | -18.16% | -28.49% | 83.86% | -14.82% | 89.02% | -38.39% | -12.07% | -30.98% | 29.73% | 43.94% | 27.89% |
| 2022 | -30.88% | -7.52% | -34.61% | -13.41% | -1.29% | 33.01% | 3.93% | 24.23% | 1.24% | -0.85% | -10.90% | -17.98% | -54.99% |
| 2021 | 11.33% | -21.08% | 38.47% | -16.85% | -16.90% | -8.76% | -16.78% | -0.16% | -10.41% | -42.90% |
Benchmark Metrics
Recursion Pharmaceuticals, Inc. has an annualized alpha of -27.33%, beta of 2.34, and R2 of 0.18 versus S&P 500 Index. Calculated based on daily prices since April 16, 2021.
- This stock participated in 204.59% of S&P 500 Index downside but only 15.60% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.18 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -27.33%
- Beta
- 2.34
- R²
- 0.18
- Upside Capture
- 15.60%
- Downside Capture
- 204.59%
Return for Risk
Risk / Return Rank
RXRX ranks 13 for risk / return — above 13% of stocks peers on PortfoliosLab. Its historical combined result is below most peers; review the five component ranks for context.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Recursion Pharmaceuticals, Inc. (RXRX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| RXRX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.13 | ||
| Sortino ratioReturn per unit of downside risk | -2.93 | ||
| Omega ratioGain probability vs. loss probability | 0.90 | 1.25 | -0.35 |
| Calmar ratioReturn relative to maximum drawdown | -0.85 | 2.00 | -2.86 |
| Martin ratioReturn relative to average drawdown | -1.25 | 8.49 | -9.74 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Recursion Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Recursion Pharmaceuticals, Inc. was 93.13%, occurring on Mar 30, 2026. The portfolio has not yet recovered.
The current Recursion Pharmaceuticals, Inc. drawdown is 92.74%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-93.13%Mar 2026 | 4y 8mo | — | 5y 21dJul 2021 - now | — |
-38.10%May 2021 | 13d | 1mo 5d | 1mo 18dApr 2021 - Jun 2021 | — |
-10.54%Apr 2021 | 1d | 2d | 2dApr 2021 - Apr 2021 | — |
-10.45%Jun 2021 | 1d | 13d | 14dJun 2021 - Jul 2021 | — |
-8.29%Apr 2021 | 1d | 6d | 7dApr 2021 - Apr 2021 | — |
Drawdown Indicators
| RXRX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.13% | -56.78% | -36.35% |
Max Drawdown (1Y)Largest decline over 1 year | -58.17% | -9.10% | -49.07% |
Max Drawdown (3Y)Largest decline over 3 years | -81.70% | -18.90% | -62.80% |
Max Drawdown (5Y)Largest decline over 5 years | -90.95% | -25.43% | -65.52% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -92.74% | -1.58% | -91.16% |
Average DrawdownAverage peak-to-trough decline | -75.79% | -10.70% | -65.09% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 39.99% | 2.14% | +37.85% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Recursion Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Recursion Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for RXRX relative to other companies in the Biotechnology industry. Currently, RXRX has a P/S ratio of 22.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for RXRX in comparison with other companies in the Biotechnology industry. Currently, RXRX has a P/B value of 1.5. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with RXRX
Add Recursion Pharmaceuticals, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with RXRX